• Users Online: 163
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 7  |  Issue : 2  |  Page : 55-61

Kidney transplant and its outcomes: Five-year single-center experience from Central India


Department of Nephrology, Government Medical College and Superspeciality Hospital, Nagpur, Maharashtra, India

Correspondence Address:
Riteshkumar Krishnanarayan Banode
Department of Nephrology, Government Medical College and Super Speciality Hospital, Beside Rashtra Sant Tukdoji Cancer Hospital, Hanuman Nagar, Manewada Road, Nagpur - 440 024, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrsm.jcrsm_61_21

Rights and Permissions

Background: Kidney transplantation has become the treatment of choice for most patients with end-stage kidney disease (ESKD). However, there is a remarkable disparity in the access and outcome of kidney transplant across the world. We present the clinical and survival data from the nephrology and kidney transplantation center for a period of 5 years in a cost-limited setting from Central India. Materials and Methods: This is a retrospective study of 66 kidney transplants performed in a single transplant center over a period of 5 years from 2016 to 2020. All data of recipients and donors were obtained from hospital records. Kaplan–Meier method was used for survival analysis. Results: Of 66 included patients, 86% were living donor and 14% were cadaveric kidney transplant. The mean age of the recipient was 30.64 ± 10.66 years. Fifty-five (83%) were male recipients and 11 (17%) were female recipients. The most common cause of ESKD in recipients was chronic glomerulonephritis (55%). The mean hemodialysis vintage was 11.04 ± 10.12 months. Seventy-four percent of donors were female and 24% of donors were male. Induction therapy with rabbit antithymocyte globulin was used in 20 (30%) and basiliximab in 21 (32%) recipients. Thirty (45%) recipients underwent graft kidney biopsy in view graft dysfunction. Acute cellular rejection was the most common cause of graft dysfunction seen in 8 (28%) of graft kidney biopsy. Graft survival and patient survival at 1, 3, and 5 years after transplant were 89%, 81%, and 77% and 90%, 84%, and 81%, respectively. Conclusions: Our observation showed that graft survival and patient survival after transplant were lower compared to other studies due to higher rejection rate and mortality due to infections. Hence, attention to immunological risk factors with proper immunologic testing pretransplant and early detection and adequate treatment of rejection episode even in cost-limited settings are suggested. Also after kidney transplant, prevention and prompt treatment of infection would offer the greatest potential to improve the chance of living longer with functioning graft.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed687    
    Printed8    
    Emailed0    
    PDF Downloaded55    
    Comments [Add]    

Recommend this journal